Researchers develop 'mini guts' to advance inflammatory bowel disease treatment

Scientists at Monash University are pioneering a new approach to understanding and treating pediatric inflammatory bowel disease (IBD) with the development of "mini guts." These are sophisticated 3D models of the intestinal lining derived from individual young patients' samples, stored alongside their associated gut bacteria.

“

I couldn't do a lot of stuff because I felt very tired. It just made my stomach hurt and cramp and when I tried to do exercise it would hurt, and I'd go to the toilet six times a day, and that was really hard for me.

This groundbreaking technology allows researchers to study IBD, including conditions like ulcerative colitis and Crohn's disease, in living tissue within a laboratory setting. Lead researcher Helen Abud explained that the organoids are a "game-changing research tool" because they enable the development and testing of new therapies without needing to involve patients directly. This significantly accelerates the research process and reduces potential risks.

“

It was a disease we'd never heard of before, so it was a new journey to us.

Ronan Somers, a 12-year-old boy battling ulcerative colitis, shared his struggles with the debilitating illness, which has frequently caused him fatigue, pain, and frequent trips to the toilet, impacting his schooling and daily life. His mother, Jasmin Alarcon, described the long and difficult journey to find effective treatment, which took 904 days after diagnosis due to the trial-and-error nature of managing the disease.

“

He went on a lot of medication that didn't work, so it was a bit of a of trial-and-error stage.

Associate Professor Edward Giles, a pediatric gastroenterologist, expressed optimism about the potential of this research. The ability to inject gut bacteria back into the organoid models allows for a detailed examination of the interaction between microbes and the intestinal lining. This, he believes, will help identify the drivers of inflammation and uncover new therapeutic targets, paving the way for more precise and personalized treatments for IBD patients.

“

The benefit is it allows us to study the disease in living tissue in the lab so we don't have to go to the patient, but it also allows us to develop and test new therapies.